Literature DB >> 18678821

The muddle of mycophenolate mofetil in myasthenia.

Michael Benatar, Lewis P Rowland.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18678821     DOI： 10.1212/01.wnl.0000324254.97372.e0

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  4 in total

1.  Satisfactory Response With Achieving Maintenance Low-Dose Prednisone in Generalized Myasthenia Gravis.

Authors:  Ahmad R Abuzinadah; Duaa Jabari; Omar Jawdat; Mamatha Pasnoor; Melanie Glenn; Laura Herbelin; April L McVey; Richard J Barohn; Mazen M Dimachkie
Journal:  J Clin Neuromuscul Dis       Date:  2018-12

2.  Myasthenia gravis exacerbation after discontinuing mycophenolate: A single-center cohort study.

Authors:  Björn Oskarsson; David M Rocke; Karsten Dengel; David P Richman
Journal:  Neurology       Date:  2016-02-05       Impact factor: 9.910

Review 3.  Current and future standards in treatment of myasthenia gravis.

Authors:  Ralf Gold; Christiane Schneider-Gold
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

Review 4.  Advances in autoimmune myasthenia gravis management.

Authors:  Shuhui Wang; Iva Breskovska; Shreya Gandhy; Anna Rostedt Punga; Jeffery T Guptill; Henry J Kaminski
Journal:  Expert Rev Neurother       Date:  2018-07-04       Impact factor: 4.618
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.